-
公开(公告)号:EP2655378B1
公开(公告)日:2017-03-01
申请号:EP11850232.7
申请日:2011-12-21
申请人: AstraZeneca AB
发明人: CSJERNYIK, Gabor , KARLSTRÖM, Sofia , KERS, Annika , KOLMODIN, Karin , NYLÖF, Martin , ÖHBERG, Liselotte , RAKOS, Laszlo , SANDBERG, Lars , SEHGELMEBLE, Fernando , SÖDERMAN, Peter , SWAHN, Britt-Marie , VON BERG, Stefan
IPC分类号: C07D491/107 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/506 , A61P25/28 , C07D401/04 , C07D235/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D491/20
CPC分类号: A61K31/497 , A61K31/4184 , A61K31/4188 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K45/06 , A61K2300/00 , C07D235/02 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D471/04 , C07D491/107 , C07D491/20
-
公开(公告)号:EP3176172A1
公开(公告)日:2017-06-07
申请号:EP17150757.7
申请日:2011-12-21
申请人: Astrazeneca AB
发明人: CSJERNYIK, Gabor , KARLSTR M, Sofia , KERS, Annika , KOLMODIN, Karin , NYLÖF, Martin , ÖHBERG, Liselotte , RAKOS, Laszlo , SANDBERG, Lars , SEHGELMEBLE, Fernando , SÖDERMAN, Peter , SWAHN, Britt-Marie , VON BERG, Stefan
IPC分类号: C07D491/107 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/506 , A61P25/28 , C07D401/04 , C07D235/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D491/20
摘要: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aß-related pathologies such as Down's syndrome, ß- amyloid angiopathy such as, but not limited to, cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
摘要翻译: 本发明涉及式(I)的化合物及其药物组合物。 此外,本发明涉及用于治疗和/或预防Aβ相关病症如唐氏综合症,β-淀粉样血管病例如但不限于脑淀粉样血管病或遗传性脑出血的疾病的治疗方法,与 认知障碍,诸如但不限于MCI(“轻度认知障碍”),阿尔茨海默病,记忆丧失,与阿尔茨海默病相关的注意力缺陷症状,与诸如阿尔茨海默病的疾病相关的神经变性或包括混合血管和退行性起源的痴呆在内的痴呆, 老年痴呆症,老年痴呆症和帕金森病相关的痴呆症。
-
公开(公告)号:EP2655378A1
公开(公告)日:2013-10-30
申请号:EP11850232.7
申请日:2011-12-21
申请人: AstraZeneca AB
发明人: CSJERNYIK, Gabor , KARLSTRÖM, Sofia , KERS, Annika , KOLMODIN, Karin , NYLÖF, Martin , ÖHBERG, Liselotte , RAKOS, Laszlo , SANDBERG, Lars , SEHGELMEBLE, Fernando , SÖDERMAN, Peter , SWAHN, Britt-Marie , VON BERG, Stefan
IPC分类号: C07D491/107 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/506 , A61P25/28 , C07D401/04 , C07D235/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D491/20
CPC分类号: A61K31/497 , A61K31/4184 , A61K31/4188 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K45/06 , A61K2300/00 , C07D235/02 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D471/04 , C07D491/107 , C07D491/20
摘要: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
-
公开(公告)号:EP3176172B1
公开(公告)日:2020-01-29
申请号:EP17150757.7
申请日:2011-12-21
申请人: Astrazeneca AB
发明人: CSJERNYIK, Gabor , KARLSTRÖM, Sofia , KERS, Annika , KOLMODIN, Karin , NYLÖF, Martin , ÖHBERG, Liselotte , RAKOS, Laszlo , SANDBERG, Lars , SEHGELMEBLE, Fernando , SÖDERMAN, Peter , SWAHN, Britt-Marie , VON BERG, Stefan
IPC分类号: C07D491/107 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/506 , A61P25/28 , C07D401/04 , C07D235/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D491/20
-
5.
公开(公告)号:EP2864296A1
公开(公告)日:2015-04-29
申请号:EP13731448.0
申请日:2013-06-20
申请人: Astrazeneca AB
发明人: KARLSTRÖM, Sofia , CSJERNYIK, Gabor , SWAHN, Britt-Marie , SANDBERG, Lars , KOLMODIN, Karin , SÖDERMAN, Peter , ÖHBERG, Liselotte
IPC分类号: C07D235/02 , A61K31/4184 , A61P25/28 , C07D401/04 , A61K31/4439
CPC分类号: C07D235/02 , A61K31/4184 , A61K31/4439 , A61K45/06 , C07D401/02 , C07D401/04
摘要: 2H-imidazol-4-amine compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating Αβ-related pathologies such as Down's syndrome, β-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration methods of therapy, and pharmaceutical compositions containing such compounds. Formula (I) wherein A is -O- or -CH
2 -, n is 1 or 1.
-
-
-
-